Attachments
- course introduction 2017_18.pdf
- The First Approved Gene Therapy Productfor Cancer.pdf
- gene therapy tools_final
- Twenty Years of European Union Support to Gene Therapy and Gene Transfer.pdf
- GT Numbers-2018.pdf
- Plasmid-based Vectors.pdf
- Viral Vectors.pdf
- Class_2&4May.pdf
- InvitedSeminar_DianaGaspar.pdf
- Invited seminar_EBekman_Gene editing and gene and cell therapy 2018.pdf
- InvitedSeminar_AntonioFiarresga.pdf
- Hanahan_Cell_2011.pdf
- Jackson et al, 2016.pdf
- Review_SC-therapies_Cancer_2014.pdf
- Class_18May.pdf
- Cancer_Challenge.pdf
- Group 1 - Therapeutically engineered induced neural stem cells are tumour-homing and inhibit progression of glioblastoma.pdf
- Group 2 - Neural Stem Cell-Mediated Enzyme-Prodrug Therapy for Glioma- Preclinical Studies.pdf
- Group 3 - Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application.pdf
- Group 4 - Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth.pdf
- Group 5 -Cancer-derived exosomes as a delivery platform of CRISPR:Cas9 confercancer cell tropism-dependent targeting.pdf
- Genetic engineering of SC to secrete anticancer proteins.pdf
- Genetic engineering of SC to express Prodrug converting enzymes.pdf
- Cell-based oncolytic viral therapy.pdf
- Cells as nanocarriers.pdf
- Exossomes and cancer.pdf
- bioethics part2 2017_2018.pdf
- bioethic cases.pdf
- Morhs case.pdf
- Thalassaemia case.pdf
- Turtleshack_com One of Three Two Headed Turtles.MPG.mp4
- Learn from DIY biologists.pdf
- Bioethics.pdf
- ClassBioethics_June1.pdf